If you have been diagnosed with CRPS or reflex sympathetic dystrophy (RSD), you may be eligible to participate in a new treatment study at Stanford Systems Neuroscience and Pain Lab (SNAPL). This trial will test if a medication called Low‐Dose Naltrexone (LDN) can reduce some or all of the signs and symptoms of CRPS/RSD. Naltrexone (at high doses) has been a FDA‐approved drug for nearly three decades. There is significant evidence to suggest that LDN can effectively treat certain types of pain, fatigue, and sleep disorders. This will be the first official study of its effectiveness for CRPS. Although the study is placebo‐controlled, all participants will have the opportunity to receive treatment for up to eight weeks.
The duration of the study lasts 14 weeks and involves seven in‐person visits to Stanford, and several weekly questionnaires and daily pain scores which can be done remotely. Stanford Neuroscience and Pain Lab (SNAPL) will provide eight weeks of LDN treatment and compensation of time for all participants.
Any person with CRPS or RSD is eligible to participate in the study, provided they:
1. Are between the ages of 18 and 65.
2. Are not pregnant or planning to become pregnant.
3. Have had CRPS for at least 1 year.
4. Have upper and/or lower extremity CRPS.
5. Have been on stable treatment for 3 months.
6. Are not using opioid analgesics or narcotics.
7. Do not have any known allergy to naltrexone or naloxone.

If you are interested in hearing more, contact our project leader today at (650) 724‐ 9320. We hope to see you soon!